Key result
Surface-engineered rosuvastatin nanoparticles enhance biopharmaceutical performance for LDL-receptor targeting.
Answers are grounded in this paper and cite their sources.
AIM: The present studies describe Quality by Design-oriented development and characterization of surface-engineered solid lipid nanoparticles (SLNs) of rosuvastatin calcium for low density lipoprotein-receptor targeting. MATERIALS & METHODS: SLNs were systematically prepared employing Compritol 888 and Tween-80. Surface modification of SLNs was accomplished with Phospholipon 90G and DSPE-mPEG-2000 as the ligands for specific targeting to the low density lipoprotein-receptors. SLNs were evaluated for size, potential, entrapment, drug release performance and gastric stability. Also, the formulations were evaluated for cellular cytotoxicity, uptake and permeability, pharmacokinetic, pharmacodynamic and biochemical studies. RESULTS & CONCLUSION: Overall, the studies ratified enhanced biopharmaceutical performance of the surface-engineered SLNs of rosuvastatin as a novel approach for the management of hyperlipidemia-like conditions.
No takes yet. Share an insight, caveat, or question.
Beg et al. (2017) studied Hyperlipidemia. Surface-engineered solid lipid nanoparticles of rosuvastatin calcium was evaluated on Biopharmaceutical performance, pharmacokinetics, and pharmacodynamics. Surface-engineered solid lipid nanoparticles of rosuvastatin calcium modified with Phospholipon 90G and DSPE-mPEG-2000 demonstrated enhanced biopharmaceutical performance for LDL-receptor targeting.
Synapse has enriched 10 related papers. Consider them for comparative context: